Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
Do you routinely transition to PO antibiotics for patients with native joint septic arthritis whom have undergone washout and the organism is not S. aureus?
Related Questions
What is your approach in managing patients with suspected super-infected pancreatic pseudocysts that are not yet mature enough for drainage?
Do you use CNS dosing of antibiotics for any portion of the treatment course in patients with infective endocarditis who have cerebral emboli?
For a patient on appropriate treatment for invasive aspergillosis, how do you determine if and when it is acceptable to reintroduce a TNF inhibitor that likely contributed to their acquisition of the infection but is considered essential for control of their inflammatory condition?
In what scenarios outside of cryptococcal meningitis do you use flucytosine as adjunctive antifungal therapy?
What are your vaccine recommendations while patients are on biologics?
What specific clinical signs or epidemiological indicators do you prioritize for early identification of Bartonella quintana infection?
How would you manage a patient with necrotizing pneumonia due to a susceptible Pseudomonas aeruginosa strain who continues to have significant purulent secretions and worsening imaging while receiving cefepime?
Would you avoid using cephalosporins in a patient with a history of cephalosporin neurotoxicity in the setting of CKD?
How do you approach using fecal microbiota therapy for recurrent Clostridioides difficile infection in immunocompromised patients?
What duration of therapy do you recommend for patients with a vascular graft infection in which the graft has been removed and another graft placed in the infected space?
